Provided by Tiger Trade Technology Pte. Ltd.

Merit Medical

68.73
-0.5800-0.84%
Post-market: 68.730.00000.00%17:00 EDT
Volume:735.76K
Turnover:50.63M
Market Cap:4.08B
PE:32.27
High:69.50
Open:69.05
Low:67.91
Close:69.31
52wk High:107.27
52wk Low:66.34
Shares:59.29M
Float Shares:57.83M
Volume Ratio:0.81
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.13
EPS(LYR):2.13
ROE:8.67%
ROA:4.75%
PB:2.57
PE(LYR):32.27

Loading ...

Merit Medical to Begin Sales of Wrapsody, Pulls Government Payment Application

Dow Jones
·
Nov 14, 2025

BRIEF-Merit Medical Provides Update On US Reimbursement And Commercial Strategies For Wrapsody Cell-Impermeable Endoprosthesis

Reuters
·
Nov 14, 2025

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for Wrapsody® Cell-Impermeable Endoprosthesis

THOMSON REUTERS
·
Nov 14, 2025

Merit Medical Systems Inc - CMS Defers Wrapsody Cie Application to 2027 Outpatient Prospective Payment System Rule

THOMSON REUTERS
·
Nov 14, 2025

Merit Medical Systems Inc - Forecasts $2 Mln-$4 Mln U.S. Revenue From Wrapsody Cie in 2025

THOMSON REUTERS
·
Nov 14, 2025

Did Positive WAVE Trial Results and Global Approvals Just Shift Merit Medical Systems' (MMSI) Investment Narrative?

Simply Wall St.
·
Nov 11, 2025

Merit Medical Releases 24-Month Efficacy Results From the Randomized Arteriovenous Fistula (Avf) Arm of the Wrapsody Arteriovenous Access Efficacy (Wave) Trial

THOMSON REUTERS
·
Nov 05, 2025

Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

GlobeNewswire
·
Nov 05, 2025

Merit Medical Completes Acquisition of C2 CryoBalloon

TIPRANKS
·
Nov 04, 2025

Merit Medical Systems Closes Acquisition of C2 CryoBalloon Device from Pentax

Reuters
·
Nov 04, 2025

Merit Medical releases efficacy results from single-arm AVG cohort of WAVE trial

TIPRANKS
·
Nov 03, 2025

Merit Medical Systems Inc - 24-Month Tlpp Reported at 41.7%

THOMSON REUTERS
·
Nov 03, 2025

Merit Medical Releases 24-Month Efficacy Results From the Single-Arm Arteriovenous Graft (Avg) Cohort of the Wrapsody Arteriovenous Access Efficacy (Wave) Trial

THOMSON REUTERS
·
Nov 03, 2025

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

GlobeNewswire
·
Nov 03, 2025

Merit Medical’s Lack of Insider Trading Disclosures Raises Investor Concerns

TIPRANKS
·
Nov 01, 2025

Merit Medical’s Earnings Call: Strong Growth Amid Challenges

TIPRANKS
·
Nov 01, 2025

Merit Medical Systems Inc : Barrington Research Raises Target Price to $106 From $103

THOMSON REUTERS
·
Oct 31, 2025

Stock Track | Merit Medical (MMSI) Soars 6.02% Pre-Market Following Multiple Analyst Target Price Hikes

Stock Track
·
Oct 31, 2025

Stock Track | Merit Medical Soars 6.02% Following Multiple Analyst Price Target Increases

Stock Track
·
Oct 31, 2025

Merit Medical Price Target Maintained With a $108.00/Share by Needham

Dow Jones
·
Oct 31, 2025